Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.

Francois Pierre CombesSherwin K B SyYing Fei LiSebastien LorenzoKohinoor DasguptaShruti KapoorMatthias HochYu-Yun Ho

Published in: Clinical pharmacokinetics (2024)

Similarity between 40 mg b.i.d. and 80 mg q.d. regimens was investigated, demonstrating similar and substantial efficacy with well-tolerated safety in patients without T315I mutation. The 200-mg b.i.d. dose was deemed safe and effective for patients with T315I mutation.

Keyphrases

chronic myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
acute lymphoblastic leukemia
prognostic factors
patient reported outcomes